DOCSLIB.ORG

COVID-19 Meeting # 13 Medical Staff Updates and Discussion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Meeting # 13 Medical Staff Updates and Discussion COVID-19 Meeting # 13 Medical Staff Updates and Discussion “Failing to prepare is preparing to fail” Benjamin Franklin July 22, 2020 PATIENT SAFETY WORK PRODUCT: CONFIDENTIAL AND PRIVILEGED INFORMATION CREATED AS PART OF LPSES – LEE HEALTH SYSTEM’S PATIENT SAFETY EVALUATION SYSTEM Lee Health Continuing Medical Education Thank you for participating in the COVID Guidelines Update • To receive CME credits for todays event: 1. Go to www.eeds.com 2. Enter code: 32drys – Code is only good for 24 hours 3. Complete the evaluation on eeds • All attendees will be muted on entry • Questions to the speaker: Use the chat option in WebEx Guiding Premise “The one thing we know- We have no idea what the ideal management of these patients really is.” We will continue to learn, modify and adapt our guidelines as more information and literature becomes known. AGENDA Provider Well Being During COVID-19 COVID-19 Convalescent Plasma Update COVID-19 ED Disposition Algorithm Guide COVID-19 Infectious Disease Update Physician Well Being During COVID-19 Ashely Chatigny DO, FAPA 5 “Don’t suffer in silence: get help for emotional distress” Dr Mehta, Radiologist, Charlotte, NCCOVID-19 Pandemic Physician Protection Act Ensures mental health coverage for health care workers http://www.chestnet.org/-/media/chesnetorg/Publications/Documents/CHEST-Physician/Vol-15- 2020/072020.ashx?la=en&hash=1A0DCDCEE946E3BC67EA0168754308144274C394 6 Current Provider Resources Agency Phone Number Florida Crisis Line 833-848-1762 National Suicide Prevention 800-273-8255 National Help Line 800-662-4357 Samsha 877-726-4727 Healthcare Professionals Center for progress/excellence 844-395-4432 mobile crisis unit 7 8 CME Thursday, July 23, 2020 9 Contacts for You! Please contact these providers through Voalte! Ashely Chatigny DO, FAPA, LPG Psychiatric Services Paul Simeone, Ph.D., VP Medical Director, Behavioral & Mental Health 10 Convalescent Plasma for the Treatment and Prevention of COVID-19 Douglas Brust, MD, PhD and the Lee Health ThankResearch You Team Convalescent Plasma for the Treatment of COVID-19: The Lee Health Experience • As of 7/20/2020, we have enrolled and transfused 296 patients • There have been no serious adverse events thought to be associated with convalescent plasma use • VERY QUICK AND DIRTY: For all patients < 90 yo and with at least 28 days of follow-up, compared to COVID-19 patients who did not receive convalescent plasma over the same period, there appears to be a signal (for all comers) indicating a 27% improvement in mortality when using convalescent plasma (10.8% vs. 14.8%) “For internal Lee Health Use Only. Do Not Forward or Distribute” Convalescent Plasma for the Treatment of COVID-19: The Lee Health Experience Additional Criteria for Referral for Enrollment in Mayo Convalescent Plasma Protocol 1) Admitted patient who has been in ED within 24 hours. 2) Radiographic evidence of pneumonia. 3) Room air oxygen saturation < 94% requiring supplemental oxygen but not mechanical ventilation. Patients will be evaluated chronologically Monday-Friday, 9 AM - 5 PM until 10 patients have been enrolled that calendar day (if plasma available). Patients admitted on weekends and holidays cannot be offered enrollment. Convalescent Plasma for the Treatment of COVID-19: The Lee Health Experience • Because of our extensive experience, the Mayo has asked us to submit our data as part of a multi-center, case-controlled efficacy analysis they are conducting for publication • The goal of this analysis is to compare outcomes (e.g. improvement in clinical status, length of stay, mortality) between controls (i.e. patients who were admitted to Lee Health with COVID-19 who did not receive convalescent plasma) and convalescent plasma patients with the same disease severity Convalescent Plasma for the Prevention of COVID-19: • Can convalescent plasma serve as a post-exposure prophylaxis (i.e. prevent infection in people who have had a significant exposure but are asymptomatic)? • We are enrolling a clinical trial and truly appreciate your help referring potential subjects • We need to evaluate asymptomatic people with a recent, significant exposure (within 72 hours) to an ill COVID-19 patient, but who are SARS-CoV-2 NP swab negative • Participants will be randomized to receive either COVID-19 convalescent plasma or control plasma to determine if plasma can prevent the development of active COVID-19 Convalescent Plasma for the Prevention of COVID-19: Participants can be: 1) Health care workers (or anyone that works in a healthcare setting--e.g. transporters, housekeeping, etc.) who were not wearing PPE and had a significant exposure to a sick COVID-19 patient OR 2) Community members who are at high risk for serious COVID-19 who have been exposed while living with/caring for a sick patient at home. Participants will be compensated for their time. Convalescent Plasma for the Prevention of COVID-19: When you are seeing new COVID-19 patients, kindly let them know that family members living them, who are asymptomatic, can contact us to enroll in a trial to see if convalescent plasma can prevent them from becoming ill To make it easy, if you identify an exposed person, just call me on my cell (239-292-7291) and I can call that person to discuss trial Or have patient or family members contact me at 239-343-8579 or E-mail [email protected] ED DISPOSITION ALGORITHM GUIDELINE TIM DOUGHERTY, MD, DACMT, FAAEM CCH MEDICAL DIRECTOR/CHAIR DEPARTMENT OF EMERGENCY MEDICINE LEE HEALTH MEDICAL DIRECTOR, DISASTER PREPAREDNESS QUICK REMINDERS… PRONING ORDER SET PRONING WORKS! DEXAMETHASONE SUMMARY (CONSIDER REVIEWING DR. LAFFERTY’S REVIEW 6/17) • NIH Recommendations (6/25/20): • Covid 19 pts mechanically ventilated • Covd-19 pts who require supplemental O2 but who are not mechanically ventilated • NOT recommended for outpatient use or those who do NOT require supplement O2 • Dosage: Oral or IV 6 mg daily for 10 days • Pregnant/Breast feeding: Prednisolone po 40 mg/ Hydrocortisone 80 mg BID RECOVERY TRIAL • 2104 patients on dexamethasone, 4321 were not • Lowered Death Risk from 40 % to 28% on Ventilators • Lowered Death Risk from 25% to 20 % for those requiring supplemental 02 • Number needed to treat: 8 pts ventilated pts, 25 pts on O2 • NOT yet published in peer reviewed article (other factors may be at play) FDA: HYDROXYCHLOROQUINE, CHLOROQUINE • June 15, 2020 Update: Based on ongoing analysis and emerging scientific data, FDA has revoked the emergency use authorization (EUA) to use hydroxychloroquine and chloroquine to treat COVID-19 in certain hospitalized patients when a clinical trial is unavailable or participation is not feasible. We made this determination based on recent results from a large, randomized clinical trial in hospitalized patients that found these medicines showed no benefit for decreasing the likelihood of death or speeding recovery. This outcome was consistent with other new data, including those showing the suggested dosing for these medicines are unlikely to kill or inhibit the virus that causes COVID-19. As a result, we determined that the legal criteria for the EUA are no longer met. Please refer to the Revocation of the EUA Letter and FAQs on the Revocation of the EUA for Hydroxychloroquine Sulfate and Chloroquine Phosphate for more information. NEW ENGLAND JOURNAL OF MEDICINE • Mild or Moderate Covid 19 • https://www.nejm.org/doi/full/10.1056/NEJMcp2009249 • Severe Covid 19 • https://www.nejm.org/doi/full/10.1056/NEJMcp2009575 MILD SYMPTOMS • In China: 81% mild/moderate disease, 14% severe disease, 5 % critical disease • Mild illness usually can recover at home • Mild: Some do progress one week after onset of symptoms • New/worsening symptoms (dyspnea) – need further evaluation • Consider Home Pulse Ox to self monitor. RISK FACTORS • Established Risk • Unclear Risk • Age greater than 65 yrs old • Kidney Disease • Cardiovascular disease • Immunosuppression • Chronic lung disease • Cancer • HTN • Uncontrolled HIV • DM • Male (?) • Obesity NEW YORK EXPERIENCE • Fever often absent (31% Northwell Health, 25% Cornell) • At Cornell, • 31% of the patients required no supplement oxygen at presentation the ED, yet subsequently deteriorated leading to intubation. • Initial Chest X-ray clear 17%, unilateral infiltrate 16%, B/L 60% • At Columbia, • Median 3 days btw hospital admission and clinical deterioration. 80% patients intubated • Chest infiltrates present 98% X-rays (median presentation 6 days after symptoms started). ED DISPOSITION? Source: Socionomics Institute WHAT WE (DON’T) KNOW? • There is No literature directly address what clinical features indicate safety for discharge • Lack of current validated risk prediction tools for ED admission/discharge criteria • Admission decision driven largely by need for supplemental oxygen or factors that may put patients with mild disease at risk for sudden deterioration out of the hospital • No single laboratory test is reliable indicator who can be discharged or admission CAN WE BASE IT ON AN X-RAY? • Chest X-ray has low sensitivity 67- 69% for diagnosis of COVID • No single investigation, including CT scanning, showed sufficient sensitivity or specificity to be used to identify patients requiring admission • Clinically hypoxic patient with clear X-ray argue against COVID as the cause of hypoxia • Slightly ill patients with normal chest X-ray still could be COVID COVID-GRAM: A CLINICAL PREDICTION RULE TO PREDICT CRITICAL ILLNESS IN HOSPITALIZED COVID-19 PATIENTS • Liang W et al. Development and Validation of a Clinical
Load more

Recommended publications
  • Outcome Reporting Bias in COVID-19 Mrna Vaccine Clinical Trials
    medicina Perspective Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials Ronald B. Brown School of Public Health and Health Systems, University of Waterloo, Waterloo, ON N2L3G1, Canada; [email protected] Abstract: Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. The present article uses clinical epidemiologic tools to critically appraise reports of efficacy in Pfzier/BioNTech and Moderna COVID-19 mRNA vaccine clinical trials. Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2, this critical appraisal shows: relative risk reduction, 95.1%; 95% CI, 90.0% to 97.6%; p = 0.016; absolute risk reduction, 0.7%; 95% CI, 0.59% to 0.83%; p < 0.000. For the Moderna vaccine mRNA-1273, the appraisal shows: relative risk reduction, 94.1%; 95% CI, 89.1% to 96.8%; p = 0.004; absolute risk reduction, 1.1%; 95% CI, 0.97% to 1.32%; p < 0.000. Unreported absolute risk reduction measures of 0.7% and 1.1% for the Pfzier/BioNTech and Moderna vaccines, respectively, are very much lower than the reported relative risk reduction measures. Reporting absolute risk reduction measures is essential to prevent outcome reporting bias in evaluation of COVID-19 vaccine efficacy. Keywords: mRNA vaccine; COVID-19 vaccine; vaccine efficacy; relative risk reduction; absolute risk reduction; number needed to vaccinate; outcome reporting bias; clinical epidemiology; critical appraisal; evidence-based medicine Citation: Brown, R.B.
    [Show full text]
  • Ethics of Vaccine Research
    COMMENTARY Ethics of vaccine research Christine Grady Vaccination has attracted controversy at every stage of its development and use. Ethical debates should consider its basic goal, which is to benefit the community at large rather than the individual. accines truly represent one of the mira- include value, validity, fair subject selection, the context in which it will be used and Vcles of modern science. Responsible for favorable risk/benefit ratio, independent acceptable to those who will use it. This reducing morbidity and mortality from sev- review, informed consent and respect for assessment considers details about the pub- eral formidable diseases, vaccines have made enrolled participants. Applying these princi- lic health need (such as the prevalence, bur- substantial contributions to global public ples to vaccine research allows consideration den and natural history of the disease, as health. Generally very safe and effective, vac- of some of the particular challenges inherent well as existing strategies to prevent or con- cines are also an efficient and cost-effective in testing vaccines (Box 1). trol it), the scientific data and possibilities way of preventing disease. Yet, despite their Ethically salient features of clinical vac- (preclinical and clinical data, expected brilliant successes, vaccines have always been cine research include the fact that it involves mechanism of action and immune corre- controversial. Concerns about the safety and healthy subjects, often (or ultimately) chil- lates) and the likely use of the vaccine (who untoward effects of vaccines, about disturb- dren and usually (at least when testing effi- will use and benefit from it, safety, cost, dis- ing the natural order, about compelling indi- cacy) in very large numbers.
    [Show full text]
  • COVID-19 Vaccine Trials
    COVID-19 VACCINE TRIALS SUMMARY OF PFIZER AND MODERNA COVID-19 VACCINE RESULTS Some of the most common concerns voiced involve the A review of unblinded reactogenicity data from the speed with which these vaccines were developed and final analysis which consisted of a randomized subset whether they are safe or not. How were the companies of at least 8,000 participants 18 years and older in able to get these vaccines developed and ready for the phase 2/3 study demonstrates that the vaccine distribution so fast? Were they tested in persons who was well tolerated, with most solicited adverse events are most vulnerable? Are the vaccines safe? resolving shortly after vaccination. Even though COVID-19 vaccines were developed at While the vaccine was well tolerated overall, and side an extraordinary speed, companies were required effects lasted for only a day or two, persons taking to take all of the regulatory and operational steps the vaccine should be aware that the side effects normally required for all vaccine trials, so none of are more than is seen in general for the flu vaccine these steps were skipped. What did occur that does and be prepared for them. Most side effects were not normally occur was some upfront financial mild to moderate and included injection-site pain, assistance from the federal government (Moderna redness and swelling at the injection site, fatigue/ accepted, Pfizer declined) and federal regulatory tiredness, headache, chills, muscle pain, and joint agencies working closely with the companies, pain. “Severe” side effects, defined as those that providing near real-time data with companies prevent persons from continuing daily activities were receiving review and advice more quickly.
    [Show full text]
  • Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
    Review Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines Puna Maya Maharjan 1 and Sunghwa Choe 2,3,* 1 G+FLAS Life Sciences, 123 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si 28161, Korea; punamaya.maharjan@gflas.com 2 G+FLAS Life Sciences, 38 Nakseongdae-ro, Gwanak-gu, Seoul 08790, Korea 3 School of Biological Sciences, College of Natural Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea * Correspondence: [email protected] Abstract: The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco- produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical Citation: Maharjan, P.M.; Choe, S. trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more Plant-Based COVID-19 Vaccines: neutralizing antibody responses compared to those present in a convalescent patient’s plasma.
    [Show full text]
  • Considerations for the Design of Vaccine Efficacy Trials During Public Health Emergencies
    bioRxiv preprint doi: https://doi.org/10.1101/261875; this version posted February 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Considerations for the design of vaccine efficacy trials during public health emergencies Natalie E. Dean1*, Pierre-Stéphane Gsell2, Ron Brookmeyer3, Victor De Gruttola4, Christl A. Donnelly5, M. Elizabeth Halloran6,7, Momodou Jasseh8, Martha Nason9, Ximena Riveros2, Conall Watson10, Ana Maria Henao-Restrepo2, Ira M. Longini, Jr.1* 1Department of Biostatistics, University of Florida, Gainesville, FL, USA. 2World Health Organization, Geneva, Switzerland. 3Department of Biostatistics, University of California, Los Angeles, CA, USA. 4Department of Biostatistics, Harvard University, Boston, MA, USA. 5MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK. 6Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 7Department of Biostatistics, University of Washington, Seattle, WA, USA. 8Medical Research Council, Banjul, The Gambia. 9Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA. 10Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. *To whom correspondence should be addressed: [email protected] or [email protected], Dauer Hall, PO Box 117450, Gainesville, FL 32611, USA. +1 (352) 294-1945 One Sentence Summary: As part of the WHO research and development Blueprint for action to prevent epidemics, we describe key considerations for the design and analysis of trials and studies to evaluate experimental vaccines during public health emergencies.
    [Show full text]
  • Enrolling Minors in COVID-19 Vaccine Trials
    Prepublication Release Enrolling Minors in COVID-19 Vaccine Trials Kevin Mintz, PhD, E. Jardas BS, Seema Shah, JD, Christine Grady, RN PhD, Marion Danis, MD, and David Wendler, PhD DOI: 10.1542/peds.2020-040717 Journal: Pediatrics Article Type: Special Article Citation: Mintz K, Jardas E, Shah S, Grady C, Danis M, Wendler D. Enrolling minors in COVID-19 vaccine trials. Pediatrics. 2020; doi: 10.1542/peds.2020-040717 This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version. Downloaded from www.aappublications.org/news by guest on October 4, 2021 ©2020 American Academy of Pediatrics Prepublication Release Enrolling Minors in COVID-19 Vaccine Trials Kevin Mintz, PhDa, E. Jardas, BSa, Seema Shah, JDb,c,, Christine Grady, RN, PhDa, Marion Danis, MDa, and David Wendler, PhDa Affiliations: aDepartment of Bioethics, National Institutes of Health, Bethesda, Maryland; bAnn & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois; cNorthwestern University, Feinburg School of Medicine, Chicago, Illinois Address correspondence to: David Wendler, Department of Bioethics, National Institutes of Health, 10 Center Drive, Building 10, Room 1C118, Bethesda, MD 20892-1156, [email protected].
    [Show full text]
  • Vaccine Safety Monitoring
    Vaccine Safety Monitoring Vaccine Safety Vaccines are the best way to prevent serious illnesses and death from many infectious diseases. (Get Quick Facts and Resources for Kentucky Residents.) The Food and Drug Administration (FDA) adheres to rigorous testing standards before licensing vaccines. Vaccines are developed through the same general process used to develop drugs and medicines. Vaccine Development 101 A sponsor who wishes to begin clinical trials with a vaccine must apply to the FDA. In their application, they must describe the vaccine, how it is manufactured, and the quality control tests that are done. The applications must also include information about the vaccine’s safety and the results of testing in animals. If the application is approved the vaccine can be tested on people during clinical trials. These trials are typically done in three phases. Phase 1 studies are performed in a small number of closely monitored subjects. Phase 2 studies may enroll hundreds of subjects. Phase 3 trials typically enroll thousands of people. These trials are used to document vaccine effectiveness. They also provide important additional safety data required for licensing. At any stage of the studies in animals or humans, if data raise significant concerns about either safety or effectiveness, the FDA may request additional information or studies, or may halt ongoing clinical studies. After reviewing clinical trial results and the proposed vaccine label, inspecting the facility where the vaccine will be made, and reviewing the vaccine production process, the FDA may decide to license the vaccine. The FDA also authorizes Emergency Use when justified. Find out more about Emergency Use Authorizations.
    [Show full text]
  • Novel Coronavirus an International Randomised Trial of Candidate Vaccines Against COVID-19 WHO Reference Number © World Health Organization 2020
    WHO R&D Blueprint novel Coronavirus An international randomised trial of candidate vaccines against COVID-19 WHO reference number © World Health Organization 2020. All rights reserved. This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. 09 April 2020, Geneva An international randomised trial of candidate vaccines against COVID-19 - OUTLINE OF SOLIDARITY VACCINE TRIAL 09 April 2020 Table of Contents TABLE OF CONTENTS ............................................................................................................................... 2 SUMMARY .................................................................................................................................................... 3 GOAL OF THE TRIAL .................................................................................................................................. 3 ADAPTIVE DESIGN ....................................................................................................................................
    [Show full text]
  • Analysis of COVID-19 Vaccine Death Reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim Results and Analysis
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/352837543 Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim Results and Analysis Preprint · June 2021 DOI: 10.13140/RG.2.2.26987.26402 CITATIONS READS 0 6 6 authors, including: Scott Mclachlan Queen Mary, University of London 57 PUBLICATIONS 268 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Clinical Practice Guideline, Protocol and CareMap Knowledge Modelling View project Electronic Health Information Security and Privacy View project All content following this page was uploaded by Scott Mclachlan on 30 June 2021. The user has requested enhancement of the downloaded file. Analysis of COVID-19 vaccine death reports from the Vaccine Adverse Events Reporting System (VAERS) Database Interim Results and Analysis Scott McLachlan, Magda Osman, Kudakwashe Dube, Patience Chiketero, Yvonne Choi, Norman Fenton Risk and Information Management, Queen Mary University of London, UK Birmingham Law School, University of Birmingham, UK School of Biological and Chemical Sciences, Queen Mary University of London, UK School of Fundamental Sciences, Massey University, NZ Occupational Health and Wellbeing, Network Rail, UK Health Informatics and Knowledge Engineering Research (HiKER) Group Abstract Clinically trained reviewers have undertaken a detailed analysis of a sample of the early deaths reported in VAERS (250 out of the 1644 deaths recorded up to April 2021). The focus is on the extent to which the reports enable us to understand whether the vaccine genuinely caused or contributed to the deaths. Contrary to claims that most of these reports are made by lay-people and are hence clinically unreliable, we identified health service employees as the reporter in at least 67%.
    [Show full text]
  • FDA Briefing Document: Pfizer-Biontech COVID-19 Vaccine
    Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020 FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine Sponsor: Pfizer and BioNTech Table of Contents List of Tables ............................................................................................................................. 3 List of Figures ............................................................................................................................ 4 Glossary..................................................................................................................................... 5 1. Executive Summary ............................................................................................................... 6 2. Background ............................................................................................................................ 7 2.1. SARS-CoV-2 Pandemic ................................................................................................ 7 2.2. EUA Request for the Pfizer and BioNTech COVID-19 Vaccine BNT162b2 .................... 8 2.3. U.S. Requirements to Support Issuance of an EUA for a Biological Product ........................................................................................................................... 8 2.4. Applicable Guidance for Industry ................................................................................... 9 2.5. Safety and Effectiveness Information Needed to Support an EUA ................................. 9 2.6. Continuation
    [Show full text]
  • Early Efficacy from Covid-19 Phase 3 Vaccine Studies
    Emerging Challenges to the Development of Covid-19 Vaccines Clinical Development & Operations SWAT Team | Thursday January 28, 2021 Workshop Agenda Time (CET) Topic Speaker(s) 15:00 – 15:10 Welcome & Meeting Objectives Peter Dull PART 1: Path to approval of additional Covid-19 vaccines Status of EUA/Licensure and vaccine use globally and key updates from previous workshops, 15:15 – 15:35 Peter Dull including correlates of protection 15:35 – 15:45 The ethics of placebo-controlled COVID-19 efficacy studies when vaccines are available Joseph Millum Placebo-controlled efficacy studies: Possibilities and Challenges – Alternative trial designs Alan Fix & 15:45 – 16:05 based on clinical endpoints and non-inferiority assessment based on immunogenicity Dean Follmann Phase 4 clinical studies: post authorization study designs to support accelerated or conditional 16:05 – 16:15 Daniel Feikin approvals Moderated by: 16:15 – 16:45 PANEL DISCUSSION: Practical paths to approval of vaccines still in development Peter Dull 16:45 – 16:50 Break Privileged and confidential 2 Workshop Agenda continued Time (CET) Topic Speaker(s) PART 2: Clinical development gaps – optimizing vaccination schedules for currently available Covid-19 vaccines Post-infection and vaccine-induced immune responses against SARS-CoV-2: summary of 17:00 – 17:15 Shabir Madhi impact of new variants 17:15 – 17:30 Heterologous prime-boost & prolonged dosing interval: Immunologic considerations Arnaud Didierlaurent 17:30 – 17:45 Comparing COVID-19 Vaccine Schedule Combinations (Com-COV) Matthew
    [Show full text]
  • Overwhelming Evidence for Vaccine Efficacy in the Pfizer Trial: an Interim Bayesian Analysis
    Overwhelming Evidence for Vaccine Efficacy in the Pfizer Trial: An Interim Bayesian Analysis Eric-Jan Wagenmakers & Quentin F. Gronau Affiliation: Psychological Methods Unit, University of Amsterdam Email of corresponding author: [email protected] ​ Word count: 772 Address for correspondence: Eric-Jan Wagenmakers Department of Psychological Methods, room G 0.29 University of Amsterdam, Nieuwe Achtergracht 129B Letter: PO Box 15906, 1001 NK Amsterdam Parcel: Valckenierstraat 59, 1018 XE Amsterdam 1 On Monday November 9th 2020, Pfizer and BioNTech issued a press release ​ in which Pfizer ​ CEO Dr. Albert Bourla stated: “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19”. But what exactly are the initial data, and how strong is the initial evidence? From the press release we learn that “The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.” We are also told that “the evaluable case count reached 94”, and Prof. Ugur Sahin, BioNTech CEO, tells us that “We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued.” Finally, the press release states that “The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020”.
    [Show full text]